Retatrutide FAQ

No. Retatrutide has no marketing authorisation from the MHRA — or from any regulator in any country. It cannot legally be prescribed, sold or supplied anywhere, and there is no legal UK stock. It is available only through clinical trials.

No. Anything sold as retatrutide — vials, pens, “research peptides” — is an unlicensed product of unknown content and purity, and supplying it for human use is illegal in the UK. There is no exception, and “for laboratory use only” labels change nothing about the risk. See our full warning page.

Realistically no earlier than 2028 through private pharmacies, and later on the NHS. Eli Lilly plans to file for US approval in Q1 2027; UK authorisation, NICE appraisal and NHS commissioning add years. Our UK timeline page maps every stage.

In the pivotal TRIUMPH-1 trial, participants on the 12 mg dose lost an average of 28.3% of body weight over 80 weeks, and 45.3% lost at least 30%. These are trial averages with intensive support, not individual guarantees — and cross-trial comparisons with Mounjaro or Wegovy need the still-unpublished head-to-head trial to be confirmed.

So far, the pattern of the GLP-1 class: dose-related nausea, vomiting, diarrhoea and constipation, worst during dose increases, mostly settling with time. Trials also recorded a small early rise in heart rate that partially returned to baseline. Long-term safety data is still being gathered.

No. Mounjaro is tirzepatide, a dual GIP/GLP-1 agonist that is MHRA-authorised and available in the UK. Retatrutide adds a third receptor (glucagon), is more effective in trials, and is not approved anywhere. Nobody should take “retatrutide” bought as a Mounjaro substitute.

Nobody knows — no price has been announced in any country. Expect a premium launch price above existing medicines if it is authorised, with competition lowering it over time, based on how Mounjaro and Wegovy pricing developed in the UK. Any website quoting a retatrutide price today is inventing it.

Possibly, if you meet the eligibility criteria of an actively recruiting TRIUMPH study. Recruitment runs through official registries such as ClinicalTrials.gov and NHS research networks — never through paid adverts or sellers. Genuine trials never charge participants for the medicine.

Eventually, perhaps — but not soon. The pattern from tirzepatide suggests NICE appraisal and a phased NHS rollout starting years after authorisation, prioritising people at highest clinical need. On current timelines, NHS access from 2029 or later is the realistic projection.

No. Yezz sells nothing, takes no bookings, carries no affiliate links and accepts no pharmacy payment. It is an independent information site run by Medstack Ltd — the same team behind monj.co.uk — and its incentive is accuracy, because there is nothing here to buy.